Julie Olson has seen the future, and it is in polymers. A former Pfizer executive, Olson is the CEO of Mersana Therapeutics, a 12-person startup in Cambridge, Mass., that is developing a biodegradable, bioļ¾inert polymer called Fleximer, which when linked to certain anticancer agents may make the drugs more soluble, less toxic to the body, and more effective in attacking tumors. In short, Fleximer, if successful, could take a drug that has failed due to high levels of toxicity and help it succeed today.
Survey Series
For Advertisers
Swimming in a Smaller Pond
Julie Olson goes from cutting deals at Pfizer to adjusting her Big Pharma attitude for life at a startup.
(continued >>)
To continue reading this full article, you must be a subscriber to The Scientist.
You are only a few minutes away from unlimited access.
If you already have an online subscription, please Log-In Now.
New to The Scientist? Register to get access to a selection of our content, interactive features and useful tools free without a subscription.
New to The Scientist? Register to get access to a selection of our content, interactive features and useful tools free without a subscription.
Subscribe to The Scientist to get unlimited access to our premium content
Get unlimited access to this article and over 20 years of The Scientist archives. You won’t miss a word – all for as little as $4.95. Subscribe now.The Scientist offers site licenses to institutions and organizations. Recommend us to your librarian and get online access through your place or work or study.